JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-08-17 pm EDT
167.58 USD   +0.01%
08/17JOHNSON & JOHNSON : PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
PU
08/12Johnson & Johnson Ends Global Sales of Cancer-Causing Baby Powder Amid Increased Scrutiny from Consumer Litigation, Science
PR
08/12J&J to end sales of baby powder with talc globally next year
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia Drug

06/24/2022 | 12:04pm EDT


© MT Newswires 2022
All news about JOHNSON & JOHNSON
08/17JOHNSON & JOHNSON : PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regi..
PU
08/12Johnson & Johnson Ends Global Sales of Cancer-Causing Baby Powder Amid Increased Scruti..
PR
08/12J&J to end sales of baby powder with talc globally next year
AQ
08/12There are two ways to see inflation data
MS
08/12Johnson & Johnson To Discontinue Selling Talc-Based Baby Powder In 2023
MT
08/12MARKETSCREENER'S WORLD PRESS REVIEW : August 12, 2022
MS
08/12Johnson & Johnson's Janssen Secures License to WuXi's TESSA Technology
MT
08/12Johnson & Johnson to end global sales of talc-based baby powder in 2023
AQ
08/12Reuters-schedule/…
RE
08/11J&J to end sales of talc-based powder worldwide in 2023
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 604 M - -
Net income 2022 21 415 M - -
Net cash 2022 10 065 M - -
P/E ratio 2022 20,5x
Yield 2022 2,62%
Capitalization 441 B 441 B -
EV / Sales 2022 4,50x
EV / Sales 2023 4,23x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 167,58 $
Average target price 185,55 $
Spread / Average Target 10,7%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-2.04%440 598
ELI LILLY AND COMPANY14.70%294 849
PFIZER, INC.-16.56%279 832
ROCHE HOLDING AG-16.74%273 886
ABBVIE INC.4.46%252 042
NOVO NORDISK A/S4.73%238 674